Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza

NCT02469298 | Completed Phase 2 Results

• 1 other identifier: 201682
• Study Type: interventional
• Target: 45
• Locations: 3 countries
• Sites: 33

Brief Summary

Study 201682 is a Phase IIa, randomized, double blind, placebo-controlled four arm outpatient study evaluating the safety, tolerability and clinical effect of danirixin or danirixin + oseltamivir combination in comparison to placebo or oseltamivir twice daily for 5 days in otherwise healthy adults with laboratory confirmed influenza infection. Danirixin is a selective and reversible C-X-C Chemokine Receptor 2 (CXCR2) antagonist that inhibits neutrophil transmigration and activation to areas of inflammation. The study endpoints are intended to test the hypothesis that inhibition of neutrophil activation by approximately 50-60% (as previously measured by cluster of differentiation \[CD11b\] expression in response to chemokine \[C-X-C motif\] ligand 1 \[CXCL1\] stimulation ex vivo in human studies) will not impact safety parameters or worsen clinical manifestations of disease, disease-related events of interest, or viral load, and may possibly improve these parameters when administered within 48 hours of symptom onset. The aim of this exploratory study is to obtain data on the safety, tolerability and clinical effect of GSK1325756 (danirixin \[DNX\]) alone or in combination with oseltamivir (OSV) in otherwise healthy adults with acute, uncomplicated influenza prior to future evaluation in hospitalized patients with complicated influenza. The primary objective is to assess safety and tolerability of DNX with and without a neuraminidase inhibitor through the evaluation of AEs, SAEs, clinical laboratory tests, vital signs, and electrocardiogram (ECG) parameters. Safety assessments will also include an assessment of disease related events (DREs) of interest and associated antibiotic use. The Influenza Intensity and Impact Questionnaire (FluiiQ™) will be used in the study to document patient reported outcomes (PROs). The screening visit in Australia will be composed of a pre-screen for influenza infection with an influenza rapid antigen test followed by a screen for the remaining eligibility criteria for those subjects with a positive result on the influenza rapid antigen test. FluiiQ is trademark owned by Measured Solutions for Health Private Limited.

Conditions

Virus Diseases

Keywords

acute, uncomplicated influenza; Danirixin; oseltamivir

Outcome Measures

Primary Outcomes (24)

• Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

  AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.

  Up to Day 28/withdrawal

• Change From Baseline in Hematology Parameters-Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Total Absolute Neutrophil Count [Total ANC]), Platelet Count and White Blood Cell (WBC) Count

  Hematology parameters included Basophils, Eosinophils, Lymphocytes, Monocytes, Total neutrophils (Total ANC), Platelet count and WBC count. Blood samples were collected on Day 1, Day 3, Day 5 and Day28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Change From Baseline in Hematology Parameters- Hemoglobin

  Hematology parameters included Hemoglobin. Blood samples were collected on Day 1, Day 3, Day 5 and Day28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Change From Baseline in Hematology Parameters- Hematocrit

  Hematology parameters included Hematocrit. Blood samples were collected on Day 1, Day 3, Day 5 and Day28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Change From Baseline in Hematology Parameters- Mean Corpuscle Hemoglobin (MCH)

  Hematology parameters included Mean corpuscle hemoglobin (MCH). Blood samples were collected on Day 1, Day 3, Day 5 and Day28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Change From Baseline in Hematology Parameters- Mean Corpuscle Volume (MCV)

  Hematology parameters included Mean corpuscle volume (MCV). Blood samples were collected on Day 1, Day 3, Day 5 and Day28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Change From Baseline in Hematology Parameters- Red Blood Cell (RBC) Count and Reticulocytes Count

  Hematology parameters included RBC count and Reticulocytes count. Blood samples were collected on Day 1, Day 3, Day 5 and Day28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Change From Baseline in Clinical Chemistry Parameters- Albumin and Total Protein

  Clinical chemistry parameters included Albumin and Total protein. Blood samples were collected on Day 1, Day 3, Day 5 and Day28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Change From Baseline in Clinical Chemistry- Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST) and Gamma Glutamyl Transferase (GGT)

  Clinical chemistry parameters included Alkaline phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase and Gamma Glutamyl Transferase. Blood samples were collected on Day 1, Day 3, Day 5 and Day28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Change From Baseline in Clinical Chemistry Parameters- Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid

  Clinical chemistry parameters included Direct Bilirubin, Total Bilirubin, Creatinine and Uric acid. Blood samples were collected on Day 1, Day 3, Day 5 and Day28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Change From Baseline in Clinical Chemistry Parameters- Calcium, Carbon Dioxide (CO2) Content/ Bicarbonate, Glucose, Potassium, Sodium and Urea/Blood Urea Nitrogen (BUN)

  Clinical chemistry parameters included Calcium, CO2 content/ Bicarbonate, Glucose, Potassium, Sodium and Urea/(BUN). Blood samples were collected on Day 1, Day 3, Day 5 and Day 28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Change From Baseline in Urinalysis Parameters- Urine pH

  Urinalysis parameters included urine pH. pH is calculated on a scale of 0 to 14, such that, the lower the number, more acidic the urine and higher the number, more alkaline the urine with 7 being neutral. Urinalysis was done on Day 1, Day 5 and Day 28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1), Day 5 and Day 28/withdrawal

• Change From Baseline in Urinalysis Parameters- Urine Specific Gravity

  Urinalysis parameter included Urine specific gravity and was measured on Day 1, Day 5 and Day 28. Urinary specific gravity is a measure of the concentration of solutes in the urine. It measures the ratio of urine density compared with water density and provides information on the kidney's ability to concentrate urine. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1), Day 5 and Day 28/withdrawal

• Number of Participants With Maximum Post-baseline Urine Dipstick Abnormalities- Urine Occult Blood (Dipstick)

  The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of urine occult blood can be read as negative, Trace, 1+, 2+, 3+ and 4+, indicating proportional concentrations in the urine sample. Assessments recorded on Day 1 were considered as Baseline.

  Up to Day 28/withdrawal

• Number of Participants With Maximum Post-baseline Urine Dipstick Abnormalities- Urine Glucose (Dipstick)

  The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of urine glucose can be read as negative, Trace, 1+ or 1/4 gram per deciliter (G/dL), 2+ OR 1/2 G/dL, 3+ or 1 G/dL and 4+ indicating proportional concentrations in the urine sample. Assessments recorded on Day 1 were considered as Baseline.

  Up to Day 28/withdrawal

• Number of Participants With Maximum Post-baseline Urine Dipstick Abnormalities- Urine Protein (Dipstick)

  The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of urine protein can be read as negative, Trace, 1+, 2+, 3+ and 4+, indicating proportional concentrations in the urine sample. Assessments recorded on Day 1 were considered as Baseline.

  Up to Day 28/withdrawal

• Change From Baseline in Vital Signs- Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)

  Vital signs were measured in semi-supine position after 5 minutes rest and included systolic and diastolic blood pressure. Three readings of blood pressure were taken; the first reading was rejected and the second and third readings were averaged to give the measurement to be recorded. Vital signs were obtained on Baseline (Day 1), Day 3, Day 5, Day 8, Day 14 and Day 28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Change From Baseline in Vital Signs- Heart Rate (HR)

  Vital signs were measured in semi-supine position after 5 minutes rest and included HR. Three readings of pulse rate were taken; the first reading was rejected and the second and third readings were averaged to give the measurement to be recorded. Vital signs were obtained on Day 1, Day 3, Day 5, Day 8, Day 14 and Day 28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Change From Baseline in Vital Signs- Respiration Rate (RR)

  Vital signs were measured in semi-supine position after 5 minutes rest and included RR. RR was obtained on Day 1, Day 3, Day 5, Day 8, Day 14 and Day 28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Change From Baseline in Vital Signs- Temperature

  Vital signs were measured in semi-supine position after 5 minutes rest and included temperature. Oral temperature was obtained on Day 1, Day 3, Day 5, Day 8, Day 14 and Day 28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Change From Baseline in Vital Signs- Percent Oxygen in Blood (POB)

  Vital signs were measured in semi-supine position after 5 minutes rest and included POB. POB was obtained on Baseline (Day 1), Day 3, Day 5, Day 8, Day 14 and Day 28/withdrawal. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Change From Baseline in Electrocardiogram (ECG) Parameters

  12-lead ECGs were obtained on Day 1, Day 3 and Day28/withdrawal using an ECG machine that automatically calculates and measures RR, PR, QRS, QT, and Corrected QT Interval using Bazette's formula (QTcB) and Corrected QT Interval using Fridericia forumula (QTcF) intervals. Assessments recorded on Day 1 were considered as Baseline. Change from Baseline was equal to Post-Dose Visit Value minus Baseline.

  Baseline (Day 1) and up to Day 28/withdrawal

• Number of Participants With Disease Related Events (DREs) of Interest

  Disease-related events of interest included Otitis media, Sinusitis, Bronchitis and Pneumonia and were captured separately from AEs and SAEs. DREs of interest were assessed and recorded by the site on all clinical visit days.

  Up to Day 28/withdrawal

• Number of Participants With DRE of Interest-associated Antibiotic Use

  Use of antibiotics for DREs of interest was monitored. Roxithromycin was used for DRE sinusitis by one participant.

  Up to Day 28/withdrawal

Secondary Outcomes (9)

• Time to Resolution of Fever Over Time Post Initiation of Treatment

  Up to Day 28/withdrawal

• Number of Afebrile Participants Over Time Post Initiation of Treatment

  Up to Day 28/withdrawal

• Number of Participants Who Used Relief Medication

  Up to Day 28/withdrawal

• Number of Hospital Admissions Due to Influenza Infection

  Up to Day 28/withdrawal

• Change From Baseline in Influenza Viral Load as Measured by Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR) From Nasopharyngeal Swabs on Day 3, Day 5, Day 8 and Day 14

  Baseline (Day 1) and Day 3, Day 5, Day 8 and Day 14

Study Arms (4)

Danirixin + Oseltamivir matching placebo

EXPERIMENTAL

Subjects will receive 75 mg oral Danirixin twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days

Drug: GSK1325756 (Danirixin); Drug: Placebo To Match Oseltamivir Phosphate

Danirixin matching placebo + Oseltamivir matching placebo

PLACEBO COMPARATOR

Subjects will receive Danirixin matching placebo twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days

Drug: Placebo To Match GSK1325756; Drug: Placebo To Match Oseltamivir Phosphate

Danirixin + Oseltamivir

EXPERIMENTAL

Subjects will receive 75 mg oral Danirixin twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days

Drug: GSK1325756 (Danirixin); Drug: Oseltamivir Phosphate

Danirixin matching placebo + Oseltamivir

ACTIVE COMPARATOR

Subjects will receive Danirixin matching placebo twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days

Drug: Placebo To Match GSK1325756; Drug: Oseltamivir Phosphate

Interventions

GSK1325756 (Danirixin) DRUG

It will be supplied as capsule shaped white film coated tablet containing 75 mg GSK1325756 for oral use

Danirixin + Oseltamivir; Danirixin + Oseltamivir matching placebo

Placebo To Match GSK1325756 DRUG

It will be supplied as capsule shaped white film coated placebo tablet for oral use

Danirixin matching placebo + Oseltamivir; Danirixin matching placebo + Oseltamivir matching placebo

Oseltamivir Phosphate DRUG

It will be supplied as size 0 Swedish Orange capsule containing 75 mg Oseltamivir phosphate and overfill of pre-gelatinized starch for oral use

Danirixin + Oseltamivir; Danirixin matching placebo + Oseltamivir

Placebo To Match Oseltamivir Phosphate DRUG

It will be supplied as size 0 Swedish Orange capsule containing pre-gelatinized starch and magnesium stearate for oral use

Danirixin + Oseltamivir matching placebo; Danirixin matching placebo + Oseltamivir matching placebo

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Between 18 and 64 years of age inclusive, at the time of signing the informed consent;
• Onset of influenza-like illness symptoms within 48 hours prior to study enrollment. Onset of symptoms is defined as the time when the subject's temperature was measured as elevated (\>=38.0°C \[\>=100.4°F\]) OR the time when the subject first experienced at least one symptom (cough, sore throat, nasal congestion, headache, feeling feverish, body aches and pains, or fatigue);
• Subjects have an oral temperature \>=38.0°C (\>=100.4°F) at screening visit or history of feeling feverish within the 24 hours prior to screening visit;
• At least one respiratory symptom (cough, sore throat, nasal congestion) and at least one systemic symptom (headache, body aches and pain, fatigue) due to influenza infection;
• A positive influenza rapid antigen test;
• Body weight \>60 Kilogram (kg) for men and \>45 kg for women; and Body Mass Index (BMI) between 19 to 35 kilogram per meters squared (kg/m\^2), inclusive;
• Male or Female subjects could be eligible if :
• Male subjects with female partners of child-bearing potential must comply with the following contraception requirements from the time of first dose of study medication until at least 36 hours (five half-lives) of study medication after the last dose of study medication:
• Vasectomy with documentation of azoospermia; Male condom plus partner use of one of the following contraceptive options: Contraceptive subdermal implant; Intrauterine device or intrauterine system; Oral Contraceptive, either combined or progestogen alone; Injectable progestogen; Contraceptive vaginal ring ; Percutaneous contraceptive patches; This is an all-inclusive list of those methods that meet the following GlaxoSmithKline (GSK) definition of highly effective: having a failure rate of less than 1% per year when used consistently and correctly and, when applicable, in accordance with the product label. For non-product methods (e.g., male sterility), the investigator determines what is consistent and correct use. The GSK definition is based on the definition provided by the International Conference on Harmonisation (ICH). The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception;
• Female subject: is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotrophin \[hCG\] test), not lactating, and at least one of the following conditions applies
• Non-reproductive potential defined as:
• Pre-menopausal females with one of the following: documented Tubal ligation; Documented Hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; Hysterectomy; Documented Bilateral oophorectomy; Postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone \[FSH\] and estradiol levels consistent with menopause). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study.
• Reproductive potential agrees to follow one of the options listed below in the GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) requirements from the time of screening, during dosing, and until at least 36 hrs after the last dose of study medication and completion of the follow-up visit.
• GSK List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) meeting GSK criteria of highly effective: having a failure rate of less than 1% per year when used consistently and correctly and, when applicable, in accordance with the product label. This list does not apply to FRP with same sex partners, when this is their preferred and usual lifestyle or for subjects who are and will continue to be abstinent from penilevaginal intercourse on a long term and persistent basis.
• Contraceptive subdermal implant; Intrauterine device or intrauterine system; Combined estrogen and progestogen oral contraceptive; Injectable progestogen; Contraceptive vaginal ring; Percutaneous contraceptive patches; Male partner sterilization with documentation of azoospermia prior to the female subject's entry into the study, and this male is the sole partner for that subject.

You may not qualify if:

• \- Subject defined as being at high risk of complications from influenza infection according to the World Health Organization (WHO) Guidelines for Pharmacological Management of Pandemic Influenza A (H1N1) and other Influenza Viruses: Pregnant women; Persons of any age with chronic pulmonary disease (e.g. Mild persistent, Moderate or severe asthma, Chronic Obstruction Pulmonary Disease \[COPD\], cystic fibrosis, bronchiectasis); Persons of any age with chronic cardiac disease (e.g. congestive cardiac failure);
• Persons with metabolic disorders (e.g. diabetes); Persons with chronic renal disease, chronic hepatic disease, certain neurological conditions (including neuromuscular, neurocognitive and seizure disorders, but not including autism spectrum disorders); Hemoglobinopathies, or immunosuppression, whether due to primary immunosuppressive conditions, such as Human Immunodeficiency Virus (HIV) infection, or secondary conditions, such as immunosuppressive medication or malignancy;
• Subjects in whom treatment with an influenza antiviral is considered essential;
• Severity of illness requiring or anticipated to require in-hospital care;
• Pulse Oximetry levels \<92% (at rest on room air) at screening or requirement for supplemental oxygen;
• Any complication of respiratory tract infection, signs of severe or progressive disease, or worsening of any pre-existing medical condition at the time of enrollment, that, in the opinion of the investigator, would place the subject at an unreasonably increased risk of participation in this study;
• Suspicion or confirmation of bacterial infection (e.g. otitis media, sinusitis, bronchitis, focal pneumonia) or who are requiring oral or systemic antibiotics within one week before enrollment;
• Women who are pregnant as determined by a positive urine human chorionic gonadotrophin (hCG) test prior to dosing or women who are breastfeeding;
• Current or chronic documented history of liver disease (including Hepatitis A, B, or C), or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones); In this case "documented" refers to the outcome of the investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records). In questionable cases the subject cannot be enrolled;
• Corrected QT interval (QTc) \>450 millisecond (msec) or QTc \>480 msec in subjects with Bundle Branch Block.
• Subjects currently using or expected to use: oral or injectable Cytochrome P450 3A4 (CYP3A4) or Breast Cancer Resistance Protein (BCRP) substrates with a narrow therapeutic index, or oral or systemic glucocorticoids during the study period; Antacids can be used but should not be taken for at least 3 hours preceding and 2 hours after administration of study drug; proton pump inhibitors and histamine H2-receptor antagonists are prohibited from the screening visit until 12 hours after completion of the final dose of study treatment.
• Subjects who have taken an approved or investigational anti-influenza medication (e.g., oseltamivir, zanamivir, peramivir, laninamivir, amantadine, rimantidine, ribavirin) within the past 4 weeks before enrollment;
• Subjects who received the live attenuated influenza virus vaccine within the past 21 days;
• Subjects treated with systemic steroids or immunosuppressants within 2 weeks of study start.
• History of alcohol/drug abuse within 6 months of the study start;

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (33)

GSK Investigational Site

Palmetto Bay, Florida, 33157, United States

Location

GSK Investigational Site

Blackfoot, Idaho, 83221, United States

Location

GSK Investigational Site

Oklahoma City, Oklahoma, 73120, United States

Location

GSK Investigational Site

Medford, Oregon, 97504, United States

Location

GSK Investigational Site

Marshfield, Wisconsin, 54449, United States

Location

GSK Investigational Site

Baulkham Hills, New South Wales, 2153, Australia

Location

GSK Investigational Site

Brookvale, New South Wales, 2100, Australia

Location

GSK Investigational Site

Hinchinbrook, New South Wales, 2168, Australia

Location

GSK Investigational Site

Liverpool, New South Wales, 2170, Australia

Location

GSK Investigational Site

Browns Plains, Queensland, 4118, Australia

Location

GSK Investigational Site

Everton Plaza, Queensland, 4053, Australia

Location

GSK Investigational Site

Kedron, Queensland, 4031, Australia

Location

GSK Investigational Site

Springfield, Queensland, 4300, Australia

Location

GSK Investigational Site

Glenelg East, South Australia, 5045, Australia

Location

GSK Investigational Site

Happy Valley, South Australia, 5159, Australia

Location

GSK Investigational Site

Berwick, Victoria, 3806, Australia

Location

GSK Investigational Site

Lynbrook, Victoria, 3975, Australia

Location

GSK Investigational Site

Noble Park, Victoria, 3174, Australia

Location

GSK Investigational Site

Pakenham, Victoria, 3180, Australia

Location

GSK Investigational Site

Tarneit, Victoria, 3029, Australia

Location

GSK Investigational Site

Applecross, Western Australia, 6153, Australia

Location

GSK Investigational Site

Baldivis, Western Australia, 6171, Australia

Location

GSK Investigational Site

Claremont, Western Australia, 6010, Australia

Location

GSK Investigational Site

Morley, Western Australia, 6062, Australia

Location

GSK Investigational Site

Yokine, Western Australia, 6060, Australia

Location

GSK Investigational Site

Port Elizabeth, Eastern Cape, 6001, South Africa

Location

GSK Investigational Site

Johannesburg, Gauteng, 1818, South Africa

Location

GSK Investigational Site

Johannesburg, Gauteng, 2113, South Africa

Location

GSK Investigational Site

Moloto South, Gauteng, 1022, South Africa

Location

GSK Investigational Site

Pretoria, Gauteng, 0152, South Africa

Location

GSK Investigational Site

Middelburg, Mpumalanga, 1055, South Africa

Location

GSK Investigational Site

Western Cape, Western Province, South Africa

Location

GSK Investigational Site

Reiger Park, 1459, South Africa

Location

Related Publications (1)

• Roberts G, Chen S, Yates P, Madan A, Walker J, Washburn ML, Peat AJ, Soucie G, Kerwin E, Roy-Ghanta S. Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Clinical Effect of Danirixin in Adults With Acute, Uncomplicated Influenza. Open Forum Infect Dis. 2019 Apr 22;6(4):ofz072. doi: 10.1093/ofid/ofz072. eCollection 2019 Apr.

  PMID: 31024969 BACKGROUND

MeSH Terms

Conditions

Virus Diseases

Interventions

danirixin; Oseltamivir

Condition Hierarchy (Ancestors)

Infections

Intervention Hierarchy (Ancestors)

Acetamides; Amides; Organic Chemicals; Cyclohexenes; Cyclohexanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 23, 2015
• First Posted: June 11, 2015
• Study Start: June 1, 2015
• Primary Completion: April 25, 2016
• Study Completion: April 25, 2016
• Last Updated: July 23, 2019
• Results First Posted: August 24, 2017

Record last verified: 2019-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
• Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Locations

ZA (8); AU (20); US (5)